Skin and oral lesions associated to imatinib mesylate therapy

Basso, Fernanda Gonçalves; Boer, Camila Cominato; Corrêa, Maria Elvira Pizzigatti; Torrezan, Marcia; Cintra, Maria Letícia; Gallottini, Marina; Santos, Paulo da Silva; Souza, Cármino Antônio de

doi:10.1007/s00520-008-0536-8

Cited by 42 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 1 summarizes reported cases of IM-associated LDE in the English language literature as found in these databases. [2347910111213141516171819] Patients of both sexes were affected. The severity of LDE due to IM varied from mild to severe and the extent of involvement varied from localized to extensive.…”

Section: Discussionmentioning

confidence: 99%

Generalized lichenoid drug eruption associated with imatinib mesylate therapy

Ghosh

2013

Indian J Dermatol

View full text Add to dashboard Cite

Imatinib mesylate (IM), an anticancer drug, has been widely used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and dermato-fibrosarcoma protuberans. Cutaneous reactions to IM have been reported to occur in varying number of patients in different case series. Non-lichenoid cutaneous reactions secondary to IM have been well-documented in the literature and are the commonest non-hematologic adverse reactions associated with its use. Lichenoid drug eruption (LDE) associated with IM therapy has rarely been reported in the literature. A case of a generalized LDE associated with IM therapy has been described here for its rarity and interesting clinical presentation. As the clinical usage of IM is increasing, one might expect an increasing number of similar patients in the future. It is thus important to realize the potential of IM to produce LDE and to differentiate this entity from idiopathic lichen planus. In the present article, the reports of IM-associated LDE, described in the PubMed and Medline database (in English language literature), have also been reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

Generalized lichenoid drug eruption associated with imatinib mesylate therapy

Ghosh

2013

Indian J Dermatol

View full text Add to dashboard Cite

show abstract

“…These lesions gradually develop after a few months of treatment [154,155,159]. Their discovery is often fortuitous, and thus, systematic oral examination of the oral cavity is required in patients treated with imatinib.…”

Section: Lichenoid Reactionsmentioning

confidence: 99%

“…7 Osteonecrosis of the jaw induced by the association of bevacizumab and denosumab erosive, or atrophic lesions. They are preferentially localized on the buccal or lingual mucosa [153,[157][158][159].…”

Section: Lichenoid Reactionsmentioning

confidence: 99%

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Vigarios

Epstein

Sibaud

2017

Support Care Cancer

135

136

View full text Add to dashboard Cite

Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (Bstomatitis,^Bmucosal inflammation,^Bmucositis^) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. In addition, they frequently affect more than 20% of treated patients and can lead to a significant morbidity or permanent treatment discontinuation. Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the BOsler-Weber-Rendu-like syndrome^described with the antibody-drug conjugate, TDM-1. Finally, we provide, to our knowledge, the first available structured data on oral toxicities induced by the new recently FDA-and EMA-approved monoclonal antibodies targeting PD-1. Clinical management of these targeted therapy-related oral changes is also discussed.

show abstract

“…Adverse reactions induced by imatinib mesylate include hematologic responses and non-hematologic responses, including nausea, vomiting, diarrhea, myalgia, edema, and skin rash1,2. The cutaneous adverse reactions commonly induced by imatinib mesylate (Gleevec™) may be non-specific such as exanthematous rash, pruritus, and edema, or may show eruptions with distinctive clinical characteristics, as in Stevens-Johnson syndrome3, acute generalized exanthematous pustulosis4,5, exfoliative dermatitis6-8, psoriasiform drug eruption or exacerbation of psoriasis9,10, pityriasis rosea -like eruption11,12, and oral lichenoid reaction13,14.…”

Section: Discussionmentioning

confidence: 99%

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Cho

Kim

et al. 2011

Ann Dermatol

View full text Add to dashboard Cite

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.

show abstract

Skin and oral lesions associated to imatinib mesylate therapy

Abstract: Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.

Cited by 42 publications

References 12 publications

Generalized lichenoid drug eruption associated with imatinib mesylate therapy

Generalized lichenoid drug eruption associated with imatinib mesylate therapy

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Contact Info

Product

Resources

About